Federal Official Gazette
OPERATIONAL RESOLUTION ANS No. 3,113, OF MARCH 13, 2026
Provides for the decree of extrajudicial liquidation of ORION PROMOÇÕES E REPRESENTAÇÕES LTDA.
OPERATIONAL RESOLUTION ANS No. 3,111, OF MARCH 13, 2026
Provides for the decree of extrajudicial liquidation of AP AREAL PARTICIPAÇÕES LTDA.
OPERATIONAL RESOLUTION ANS No. 3,114, OF MARCH 13, 2026
Provides for the order to transfer the portfolio of the health plan operator ATÍVIA SERVIÇOS DE SAÚDE S/A.
OPERATIONAL RESOLUTION ANS No. 3,115, OF MARCH 13, 2026
Provides for the order to transfer the portfolio of the health plan operator UNIMED OESTE DO PARÁ – COOPERATIVA DE TRABALHO MÉDICO. OPERATIONAL RESOLUTION ANS No. 3,112, OF MARCH 13, 2026 Provides for the decree of extrajudicial liquidation of ASSISTÊNCIA MÉDICA GLOBAL – AMEG LTDA.
ANS news
Cosaúde holds its 49th technical meeting
The meetings will be held on Mar 24 and 25, 2026. See the schedule
Mar 25, 2026:
SHIFT
TECHNOLOGY
INDICATION FOR USE
9:00 a.m. to 12:00 p.m.
UAT 186 – Encorafenib in combination with cetuximab
(Analysis of the Social Participation contributions)
First-line treatment of adult patients with BRAF V600E+ metastatic colorectal cancer
UAT 189 – Osimertinib
(Analysis of the Social Participation contributions)
First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumor presents EGFR deletion mutations, in combination with pemetrexed and platinum-based chemotherapy
2:00 p.m. to 5:00 p.m.
UAT 183 – Evolocumab
(Preliminary Discussion)
Treatment of hypercholesterolemia in adults who have recently suffered a severe atherosclerotic cardiovascular event and are outside the LDL-c target for patients at very high cardiovascular risk
General Announcements
Open public consultations
- CP 168. Subject: CP opened to receive criticism and suggestions regarding the proposed amendment of Normative Resolutions No. 516 and 521, of 2022. Deadline: Feb 23, 2026 to Apr 9, 2026.
- CP 169. Purpose: to receive contributions related to the proposed updates to the List of Health Procedures and Events (Rol). Deadline: Mar 11, 2026 to Mar 30, 2026.
Scheduled public hearings
- AP 64. Public Hearing No. 64 aims to gather contributions regarding the unfavorable preliminary recommendation for the technology: (i) UAT 193 – Olaparib as monotherapy – Treatment of adult patients with metastatic castration-resistant prostate cancer with mutations in the BRCA1 and/or BRCA2 genes, whose disease has progressed after prior treatment with a new hormonal agent. Date: March 20, 2026, from 9:30 a.m. to 11:00 a.m.
Open public calls for input
There is no open public call for input.
Open public calls
No updates.
Other news
Private health entities launch institute to strengthen the sector
Source: veja.abril.com.br · read the full article
Company may not downgrade health plan of employee on sickness benefit
Source: veja.abril.com.br · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.